Through engineering and selection strategies, we have created novel cancer-killing oncolytic viruses (OVs) that are selective for tumours but are unable to grow in normal tissues. A critical component of the therapeutic activity of this class of therapeutics is the induction of an anti-tumour immune response, which can be suppressed in many tumours. One strategy […]
Read More